These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. [Multiform clinical manifestations in progressive muscular dystrophy]. Badalian LO; Dunaevskaia GN Klin Med (Mosk); 1973 Apr; 51(4):111-5. PubMed ID: 4704249 [No Abstract] [Full Text] [Related]
26. Efficient and fast functional screening of microdystrophin constructs in vivo and in vitro for therapy of duchenne muscular dystrophy. Jørgensen LH; Larochelle N; Orlopp K; Dunant P; Dudley RW; Stucka R; Thirion C; Walter MC; Laval SH; Lochmüller H Hum Gene Ther; 2009 Jun; 20(6):641-50. PubMed ID: 19239382 [TBL] [Abstract][Full Text] [Related]
27. Current understanding of dystrophin-related muscular dystrophy and therapeutic challenges ahead. Zhou GQ; Xie HQ; Zhang SZ; Yang ZM Chin Med J (Engl); 2006 Aug; 119(16):1381-91. PubMed ID: 16934185 [TBL] [Abstract][Full Text] [Related]
28. Exercise-induced stem cell activation and its implication for cardiovascular and skeletal muscle regeneration. Wahl P; Brixius K; Bloch W Minim Invasive Ther Allied Technol; 2008; 17(2):91-9. PubMed ID: 18465444 [TBL] [Abstract][Full Text] [Related]
29. Immobility reduces muscle fiber necrosis in dystrophin deficient muscular dystrophy. Kimura S; Ikezawa M; Nomura K; Ito K; Ozasa S; Ueno H; Yoshioka K; Yano S; Yamashita T; Matuskura M; Miike T Brain Dev; 2006 Aug; 28(7):473-6. PubMed ID: 16516424 [TBL] [Abstract][Full Text] [Related]
30. Cardiac involvement in Fukuyama-type congenital muscular dystrophy. Nakanishi T; Sakauchi M; Kaneda Y; Tomimatsu H; Saito K; Nakazawa M; Osawa M Pediatrics; 2006 Jun; 117(6):e1187-92. PubMed ID: 16717122 [TBL] [Abstract][Full Text] [Related]
31. Merosin-deficient congenital muscular dystrophy type 1A. Buteică E; Roşulescu E; Burada F; Stănoiu B; Zăvăleanu M Rom J Morphol Embryol; 2008; 49(2):229-33. PubMed ID: 18516331 [TBL] [Abstract][Full Text] [Related]
32. Expression profiling of muscles from Fukuyama-type congenital muscular dystrophy and laminin-alpha 2 deficient congenital muscular dystrophy; is congenital muscular dystrophy a primary fibrotic disease? Taniguchi M; Kurahashi H; Noguchi S; Sese J; Okinaga T; Tsukahara T; Guicheney P; Ozono K; Nishino I; Morishita S; Toda T Biochem Biophys Res Commun; 2006 Apr; 342(2):489-502. PubMed ID: 16487936 [TBL] [Abstract][Full Text] [Related]
33. Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Khakoo AY; Yeh ET Nat Clin Pract Oncol; 2008 Nov; 5(11):655-67. PubMed ID: 18797437 [TBL] [Abstract][Full Text] [Related]
34. [Family study allows more optimistic prognosis and genetic counselling in a child with a deletion of exons 50-51 of the dystrophin gene]. Lesca G; Testard H; Streichenberger N; Pelissier JF; Lestra C; Burel E; Jonveaux P; Michel-Calemard L Arch Pediatr; 2007 Mar; 14(3):262-5. PubMed ID: 17258443 [TBL] [Abstract][Full Text] [Related]
35. PGD for dystrophin gene deletions using fluorescence in situ hybridization. Malmgren H; White I; Johansson S; Levkov L; Iwarsson E; Fridström M; Blennow E Mol Hum Reprod; 2006 May; 12(5):353-6. PubMed ID: 16608904 [TBL] [Abstract][Full Text] [Related]
36. Cardiac involvement in the muscular dystrophies. Silvestri NJ; Ismail H; Zimetbaum P; Raynor EM Muscle Nerve; 2018 May; 57(5):707-715. PubMed ID: 29130502 [TBL] [Abstract][Full Text] [Related]
37. New POMT2 mutations causing congenital muscular dystrophy: identification of a founder mutation. Yanagisawa A; Bouchet C; Van den Bergh PY; Cuisset JM; Viollet L; Leturcq F; Romero NB; Quijano-Roy S; Fardeau M; Seta N; Guicheney P Neurology; 2007 Sep; 69(12):1254-60. PubMed ID: 17634419 [TBL] [Abstract][Full Text] [Related]
38. Dominant-negative inhibition of Ca2+ influx via TRPV2 ameliorates muscular dystrophy in animal models. Iwata Y; Katanosaka Y; Arai Y; Shigekawa M; Wakabayashi S Hum Mol Genet; 2009 Mar; 18(5):824-34. PubMed ID: 19050039 [TBL] [Abstract][Full Text] [Related]